GSK has announced a 50/50 joint venture with leading Indian vaccines company, Biological E, for the early stage research and development of a six-in-one combination paediatric vaccine to help ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

GlaxoSmithKline has thrown its financial ... the pharma industry has turned its attention to synthetic molecules and biologics like antibodies. LifeMine has developed an industrialised, genomics ...

The recommendations were made in a closed session with representatives from CBER, the CDC and Department of Defense.

The state-of-the-art biologics facility, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, from Emergent ...

Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...

Expected to enhance global innovator flexibility with biologics drug substance facility in Baltimore BANGALORE, India, March ...